Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to examine the safety, tolerability and pharmacokinetics of TC-5619
in elderly subjects with and without Alzheimer's disease. Group 1 includes elderly subjects
with Alzheimer's disease to receive TC-5619 or placebo for 28 days to evaluate safety and
tolerability. Group 2 includes healthy elderly subjects in a dose escalation design to
receive TC-5619 or placebo for 10 days to evaluate safety, tolerability and pharmacokinetics.